Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.

Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, Moscicki AB, Mahmud SM, Wheeler CM, Rivera-Paredez B, Hernández-López R, León-Maldonado L, Salmerón J; FRIDA Study Group.

JAMA Netw Open. 2019 Nov 1;2(11):e1915781. doi: 10.1001/jamanetworkopen.2019.15781.

2.

Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis.

Kelly H, Benavente Y, Pavon MA, De Sanjose S, Mayaud P, Lorincz AT.

Br J Cancer. 2019 Nov;121(11):954-965. doi: 10.1038/s41416-019-0593-4. Epub 2019 Oct 16.

3.

Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.

Hernández-López R, Lorincz AT, Torres-Ibarra L, Reuter C, Scibior-Bentkowska D, Warman R, Nedjai B, Mendiola-Pastrana I, León-Maldonado L, Rivera-Paredez B, Ramírez-Palacios P, Lazcano-Ponce E, Cuzick J, Salmerón J; FRIDA Study Group.

Clin Epigenetics. 2019 Oct 12;11(1):140. doi: 10.1186/s13148-019-0743-9.

4.

Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics.

Giuliano AR, Nedjai B, Lorincz AT, Schell MJ, Rahman S, Banwait R, Boulware D, Sirak B, Martin-Gomez L, Abrahamsen M, Isaacs-Soriano KA, Wenig B, Chung CH, Caudell J.

Int J Cancer. 2020 Feb 15;146(4):1018-1030. doi: 10.1002/ijc.32570. Epub 2019 Jul 26.

PMID:
31304592
5.

Human Papillomavirus Research: Where Should We Place Our Bets?

Cuschieri K, Lorincz AT, Nedjai B.

Acta Cytol. 2019;63(2):85-96. doi: 10.1159/000493800. Epub 2019 Mar 28. Review.

6.

Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ, Ogilvie GS, Coldman AJ, Warman R, Reuter C, Cuzick J, Lorincz AT.

Int J Cancer. 2019 May 15;144(10):2587-2595. doi: 10.1002/ijc.31976. Epub 2018 Dec 24.

7.

Molecular progression to cervical precancer, epigenetic switch or sequential model?

Nedjai B, Reuter C, Ahmad A, Banwait R, Warman R, Carton J, Boer S, Cuzick J, Lorincz AT.

Int J Cancer. 2018 Oct 1;143(7):1720-1730. doi: 10.1002/ijc.31549. Epub 2018 Jul 3.

8.

Methylation of HPV and a tumor suppressor gene reveals anal cancer and precursor lesions.

Lorincz AT, Nathan M, Reuter C, Warman R, Thaha MA, Sheaff M, Vasiljevic N, Ahmad A, Cuzick J, Sasieni P.

Oncotarget. 2017 May 18;8(31):50510-50520. doi: 10.18632/oncotarget.17984. eCollection 2017 Aug 1.

9.

Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A immunostained sections in diagnosis of cervical intraepithelial neoplasia.

Vasiljević N, Carter PD, Reuter C, Warman R, Brentnall AR, Carton JR, Cuzick J, Lorincz AT.

Int J Cancer. 2017 Aug 15;141(4):829-836. doi: 10.1002/ijc.30783. Epub 2017 Jun 1.

10.

Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention.

Lorincz AT.

Acta Cytol. 2016;60(6):501-512. Epub 2016 Nov 3. Review.

11.

A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.

Ahmad AS, Vasiljević N, Carter P, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT.

Oncotarget. 2016 Nov 1;7(44):71833-71840. doi: 10.18632/oncotarget.12377.

12.

Validation of a DNA methylation HPV triage classifier in a screening sample.

Lorincz AT, Brentnall AR, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, Austin J, Cuzick J, Vasiljević N.

Int J Cancer. 2016 Jun 1;138(11):2745-51. doi: 10.1002/ijc.30008. Epub 2016 Feb 8.

13.

HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{EPB41L3} methylation classifier.

Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, Lorincz AT.

Cancer Biomark. 2015;15(5):669-75. doi: 10.3233/CBM-150507.

PMID:
26406956
14.

DNA methylation of PITX2 predicts poor survival in men with prostate cancer.

Vasiljević N, Ahmad AS, Carter PD, Fisher G, Berney DM, Foster CS, Cuzick J, Lorincz AT.

Biomark Med. 2014;8(9):1143-50. doi: 10.2217/bmm.14.41.

15.

Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16.

Louvanto K, Franco EL, Ramanakumar AV, Vasiljević N, Scibior-Bentkowska D, Koushik A, Cuzick J, Coutlée F, Lorincz AT; Biomarkers of Cervical Cancer Risk Study Team.

Int J Cancer. 2015 Mar 15;136(6):E638-45. doi: 10.1002/ijc.29196. Epub 2014 Sep 19.

16.

DNA methylation gene-based models indicating independent poor outcome in prostate cancer.

Vasiljević N, Ahmad AS, Thorat MA, Fisher G, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT.

BMC Cancer. 2014 Sep 6;14:655. doi: 10.1186/1471-2407-14-655.

17.

Cancer diagnostic classifiers based on quantitative DNA methylation.

Lorincz AT.

Expert Rev Mol Diagn. 2014 Apr;14(3):293-305. doi: 10.1586/14737159.2014.897610. Review.

18.

Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women.

Lazcano-Ponce E, Lőrincz AT, Torres L, Salmerón J, Cruz A, Rojas R, Hernández P, Hernández M.

Int J Cancer. 2014 Jul 1;135(1):109-16. doi: 10.1002/ijc.28639. Epub 2013 Dec 7.

19.

A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes.

Brentnall AR, Vasiljević N, Scibior-Bentkowska D, Cadman L, Austin J, Szarewski A, Cuzick J, Lorincz AT.

Int J Cancer. 2014 Sep 15;135(6):1425-32. doi: 10.1002/ijc.28790. Epub 2014 Mar 5.

20.

Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women.

Vasiljević N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT.

Gynecol Oncol. 2014 Mar;132(3):709-14. doi: 10.1016/j.ygyno.2014.02.001. Epub 2014 Feb 6.

21.

Identification of ZDHHC14 as a novel human tumour suppressor gene.

Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, Vasiljević N, Chaplin T, Xue L, Xu M, Foster JM, Karnam SS, James SY, Chioni AM, Gould D, Lorincz AT, Oliver RT, Chelala C, Thomas GM, Shipley JM, Mather SJ, Berney DM, Young BD, Lu YJ.

J Pathol. 2014 Apr;232(5):566-77. doi: 10.1002/path.4327. Epub 2014 Feb 8. Erratum in: J Pathol. 2014 Sep;234(1):134.

PMID:
24407904
22.

HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology.

Lorincz AT, Brentnall AR, Vasiljević N, Scibior-Bentkowska D, Castanon A, Fiander A, Powell N, Tristram A, Cuzick J, Sasieni P.

Int J Cancer. 2013 Aug 1;133(3):637-44. doi: 10.1002/ijc.28050. Epub 2013 Mar 7.

23.

New technologies and procedures for cervical cancer screening.

Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, J L M Meijer C, Sankaranarayanan R, J F Snijders P, Szarewski A.

Vaccine. 2012 Nov 20;30 Suppl 5:F107-16. doi: 10.1016/j.vaccine.2012.05.088. Review.

PMID:
23199953
24.

Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer.

Vasiljević N, Ahmad AS, Beesley C, Thorat MA, Fisher G, Berney DM, Møller H, Yu Y, Lu YJ, Cuzick J, Foster CS, Lorincz AT.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):35-40. doi: 10.1038/pcan.2012.47. Epub 2012 Nov 20.

25.

Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3.

Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, Shaber R, LaMere B, Clarke M, Lorincz AT, Castle PE, Schiffman M, Burk RD.

J Natl Cancer Inst. 2012 Nov 21;104(22):1738-49. doi: 10.1093/jnci/djs425. Epub 2012 Oct 23.

26.

Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S.

J Clin Oncol. 2012 Sep 1;30(25):3044-50. doi: 10.1200/JCO.2011.38.8389. Epub 2012 Jul 30.

27.

Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia.

Mirabello L, Schiffman M, Ghosh A, Rodriguez AC, Vasiljevic N, Wentzensen N, Herrero R, Hildesheim A, Wacholder S, Scibior-Bentkowska D, Burk RD, Lorincz AT.

Int J Cancer. 2013 Mar 15;132(6):1412-22. doi: 10.1002/ijc.27750. Epub 2012 Aug 20.

28.

Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial.

Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E, Nevarez PH, Acosta RD, Hernández-Avila M.

Lancet. 2011 Nov 26;378(9806):1868-73. doi: 10.1016/S0140-6736(11)61522-5. Epub 2011 Nov 1.

PMID:
22051739
29.

The Promise and the Problems of Epigenetics Biomarkers in Cancer.

Lorincz AT.

Expert Opin Med Diagn. 2011 Sep 1;5(5):375-379.

30.

Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing.

Vasiljević N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, Cuzick J, Lorincz AT.

Dis Markers. 2011;30(4):151-61. doi: 10.3233/DMA-2011-0790.

31.

A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.

Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1398-409. doi: 10.1158/1055-9965.EPI-11-0206. Epub 2011 May 20. Erratum in: Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1390-1.

32.

Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes.

Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljević N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, Lorincz AT.

Cancer Biomark. 2012;11(2-3):75-88.

PMID:
23011154
33.

A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.

Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejia I, Hernández-Avila M.

Cancer Causes Control. 2010 Oct;21(10):1693-700. doi: 10.1007/s10552-010-9598-2. Epub 2010 Jul 9.

PMID:
20617376
34.

Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture.

Lace MJ, Isacson C, Anson JR, Lörincz AT, Wilczynski SP, Haugen TH, Turek LP.

J Virol. 2009 Aug;83(15):7457-66. doi: 10.1128/JVI.00285-09. Epub 2009 May 20.

35.

A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China.

Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT.

Lancet Oncol. 2008 Oct;9(10):929-36. doi: 10.1016/S1470-2045(08)70210-9. Epub 2008 Sep 19.

PMID:
18805733
36.

Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens.

Castle PE, Sadorra M, Garcia FA, Cullen AP, Lorincz AT, Mitchell AL, Whitby D, Chuke R, Kornegay JR.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):840-3.

37.

Cervical HPV DNA detection as a predictor of a recurrent SIL diagnosis among untreated women.

Castle PE, Zemlo TR, Burk RD, Scott DR, Sherman ME, Lorincz AT, Kurman RJ, Glass AG, Rush BB, Liaw KL, Schiffman M.

J Low Genit Tract Dis. 2001 Jul;5(3):138-43.

PMID:
17050958
38.

Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ.

J Clin Microbiol. 2006 Oct;44(10):3680-5.

39.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

PMID:
16030305
40.

Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer.

Castle PE, Schiffman M, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Lorincz AT.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1311-4.

41.

A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II.

Castle PE, Garcia-Meijide M, Holladay EB, Chuke R, Payne J, Long A, Siefers H, Demuth F, Lorincz AT.

Am J Clin Pathol. 2005 Feb;123(2):250-5.

PMID:
15842050
42.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
43.

Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.

Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M.

J Clin Microbiol. 2003 Sep;41(9):4022-30.

44.

Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation.

Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M, Roth P, Lorincz AT, Gafni A, Walter SD.

Arch Pathol Lab Med. 2003 Sep;127(9):1169-75.

PMID:
12946228
45.

Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs.

Lörincz AT, Richart RM.

Arch Pathol Lab Med. 2003 Aug;127(8):959-68. Review.

PMID:
12873167
46.

Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer.

Nonnenmacher B, Pintos J, Bozzetti MC, Mielzinska-Lohnas I, Lorincz AT, Ikuta N, Schwartsmann G, Villa LL, Schiller JT, Franco E.

Int J STD AIDS. 2003 Apr;14(4):258-65.

PMID:
12716496
47.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
48.

Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.

Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR, Rush BB, Demuth F, Schiffman M.

Cancer. 2002 Nov 15;95(10):2145-51.

49.

A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.

Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M.

J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14.

PMID:
12237286
50.

Viral load of human papillomavirus and risk of CIN3 or cervical cancer.

Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M.

Lancet. 2002 Jul 20;360(9328):228-9.

PMID:
12133661

Supplemental Content

Loading ...
Support Center